Washington state gets a share of $71M multi-state settlement with Amgen over drug marketing
Oregon Attorney General Ellen Rosenblum took the lead in a multi-state $71 million settlement with drug maker Amgen Inc. in connection with its promotion of two medications. The settlement resolves allegations that Amgen unlawfully promoted Aranesp and Enbrel. Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat plaque psoriasis, among other conditions. Read the judgment document below. Specifically, the Complaint and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 18, 2015 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Texas to share in $71M California pharma company settlement
The State of Texas will build up its bank account as a result of Thousand Oaks, California-based Amgen Inc.’s decision to settle a multi-state investigation stemming from allegations it unlawfully promoted biologic medications Aranesp and Enbrel for off-label uses. Amgen has agreed to pay $71 million to 49 states, including Texas, to resolve the matter, according to Texas Attorney General Ken Paxton. Texas’ share of the settlement is $4.3 million. Aranesp is a treatment for anemia, and Enbrel… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 18, 2015 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

Amgen Reaches $71 Million Settlement With States
Amgen Inc. reached a $71 million settlement with 48 states related to allegations that the biotechnology company made unsubstantiated marketing claims about blockbuster drugs Aranesp and Enbrel, according to the New York attorney general’s office. (Source: WSJ.com: Health)
Source: WSJ.com: Health - August 18, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Express Scripts Drops Amgen Anemia Drugs From FormularyExpress Scripts Drops Amgen Anemia Drugs From Formulary
Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, said on Friday it will remove an additional 25 products from its list of preferred drugs in 2015, including anemia drugs Epogen and Aranesp. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Express Scripts drops Amgen anemia drugs from formulary
(Reuters) - Express Scripts Holding Co, the largest U.S. pharmacy benefit manager, on Friday said it will remove 25 products from its 2015 list of preferred drugs, including anemia treatments Epogen and Aranesp, both sold by Amgen Inc. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Cipla partners with Hetero to launch biosimilar anaemia drug
Actorise is a biosimilar of 'Darbepoetin alfa', which is marketed by US-based Amgen under the brand Aranesp. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 19, 2014 Category: Pharmaceuticals Source Type: news

Aranesp - Darbepoetin Alfa – Drug To...
Aranesp (darbepoetin alfa) is a drug given to patients who have chemotherapy-induced anemia (low red blood cell count). An injection of Aranesp stimulates red blood cell production, with a synthetic version of erythropoietin, a protein made in your kidneys. Learn about how it works, possible side effects, and recommendations during treatment. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 26, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Amgen settles kickback allegations with $24.9m settlement
Amgen has settled allegations that it provided kickbacks to long-term care pharmacy providers to encourage them to use its Aranesp anaemia drug instead of a rival's, by agreeing to pay $24.9m, the US Department of Justice (DOJ) announced this week. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 18, 2013 Category: Pharmaceuticals Source Type: news

Amgen to pay $25 million to settle kickback allegations
(Reuters) - Amgen Inc has agreed to pay $24.9 million to settle allegations that it provided kickbacks to long-term care pharmacy providers to entice them to use its Aranesp anemia drug instead of a rival medicine, the Department of Justice announced on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Findings Do Not Support The Use Of Darbepoetin Alfa To Treat Anemic Heart Failure Patients
Researchers from Sahlgrenska Academy, University of Gothenburg, Sweden, have found that a commonly used drug to treat anemia in heart failure patients does not improve patients' health, nor does it reduce their risk of death from heart failure. Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco and published simultaneously online by The New England Journal of Medicine... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Treatment of anaemia with darbepoetin alfa in systolic heart failure
Source: New England Journal of Medicine Area: News The findings of a study evaluating whether darbepoetin alfa improves clinical outcomes in patients with chronic systolic heart failure and non-iron-deficiency anaemia have been presented at the meeting of the American College of Cardiology and published early online in the New England Journal of Medicine.   The authors note that there is evidence to suggest that increasing haemoglobin (Hb) level with the use of erythropoiesis-stimulating agents (ESAs) may improve outcomes in patients with heart failure and anaemia, but it is not robust. Their study (Reduction of ...
Source: NeLM - Cardiovascular Medicine - March 11, 2013 Category: Cardiology Source Type: news

Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
(Cleveland Clinic) Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients -- darbepoetin alfa -- does not improve patients' health, nor does it reduce their risk of death from heart failure. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 10, 2013 Category: Global & Universal Source Type: news

Patients with HF failed to benefit from Aranesp
(Source: HemOncToday.com)
Source: HemOncToday.com - January 18, 2013 Category: Cancer & Oncology Source Type: news

Amgen Phase 3 Aranesp RED-HF trial fails to meet primary endpoint
Amgen has reported that Phase 3 Aranesp (darbepoetin alfa) RED-HF (reduction of events with darbepoetin alfa in heart failure) trial did not meet the primary endpoint of reducing the composite endpoint of time to death from any cause or first hospita… (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2013 Category: Pharmaceuticals Source Type: news

Darbepoetin Alfa Disappoints in RED-HFDarbepoetin Alfa Disappoints in RED-HF
Sponsors for the RED-HF trial say no new safety concerns arose with the drug, but treatment had no benefit over placebo in terms of reducing death from any cause or first hospital admission for worsening HF in patients with left ventricular systolic dysfunction and anemia. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news